Curasight and Curium sign global radioisotope supply agreement for uTREAT[®]

• Agreement ensures supply of non-carrier-added Lutetium-177 for uTREAT® development and commercial supply including plans for upcoming pivotal therapy trials
• The agreement supports Curasight’s strategy to leverage partnerships as it progresses its uPAR theranostic solution to diagnose and treat certain types of cancer

Copenhagen, Denmark, November 22 2024 – Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) announced today that it has entered into a clinical supply agreement with Curium – a global leader in radiopharmaceuticals – for the supply of non-carrier-added Lutetium-177 for Curasight’s uTREAT®.

The agreement announced today leverages Curium’s uniquely diversified irradiation network and large-scale manufacturing capacity recently announced in its Petten, Netherlands facility, which will largely cover the future requirements for uTREAT® Phase III trials and commercialization, in particular in the US and Europe.
 

“This important step is yet another differentiating factor that helps Curasight clearly stand out. We have seen in the past the logistical challenges associated with supply of lutetium-177 (Lu-177 or ¹⁷⁷Lu) causing delays and inefficiencies, ultimately affecting care for oncology patients waiting for their treatments.” Says CEO Ulrich Krasilnikoff and continues, “Our collaboration combines Curasight’s strengths in the clinical development of uTREAT^® and Curium’s proven expertise, capacity, and global track record in the supplying of radioisotopes,” said Curasight’s CEO Ulrich Krasilnikoff. “This agreement supports further development of our therapeutic platform, bringing us closer to fulfilling our ambition of helping a large number of brain cancer patients as a first step.”

Chait Tatineni, Curium Chief M&A Officer and Head of Curium’s licensing and partnership programs added – “As the global leader in nuclear medicine, Curium is dedicated to developing life-saving diagnostic and treatment solutions for cancer patients. We are excited about the opportunity to partner again with Curasight by ensuring a continuous supply of Lutetium-177 for their uTREAT® development program as well as in the longer term for commercial scale production. This comes in addition, to our ongoing partnering of uTRACE® for prostate cancer announced in mid-2023.”

The rapidly increasing interest from the major pharmaceutical companies in this area for use in the diagnosis and treatment of many types of cancer - means that access to these radiometals and associated supply chains very quickly becomes a scarce factor and an important competitive parameter for the development and commercialization of new products such as uTREAT and uTRACE. Therefore, this agreement is strategically very important for Curasight.

The uTREAT^® platform is part of Curasights uPAR theranostic solution, made up of its uTRACE^® diagnostic technology and its uTREAT^® targeted treatment technology. By visualizing the cancer in an enhanced and intelligent way, the uTRACE^® platform aims to provide a more accurate diagnosis in certain types of cancer including brain cancer, which can support a personalized treatment solution for each patient. The technology has been tested in multiple Phase II clinical trials with uTRACE®. Curasight will keep all rights to develop and commercialize uTREAT^® in all indications.